High-dose Secukinumab inhibits the activation of the IKBα/NFκB inflammatory pathway by neutralizing IL-17A, reduces the gene expression of pathway-related inflammatory cytokines, and thus reduces the levels of inflammatory cytokines in the lung tissue and plasma, thus alleviating lung tissue injury and improving systemic inflammation in rats with severe sepsis. The gene discussed is IL17A; the disease is Sepsis.